<DOC>
	<DOC>NCT00522587</DOC>
	<brief_summary>During this study, the pharmacodynamic interactions between sevoflurane and remifentanil will be studied.</brief_summary>
	<brief_title>Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Remifentanil</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>American Society of Anesthesia class I and II patients Aged 1860 years Scheduled for surgery under general anesthesia Weight less than 70% or more than 130% of ideal body weight Neurological disorder Diseases involving the cardiovascular system (hypertension, coronary artery disease, prior acute myocardial infarction (AMI), any valvular and/or muscular disease involving decrease of the ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/automatic implantable cardioverter defibrillator [AICD]) Pulmonary disease including asthma, severe chronic obstructive pulmonary disease (COPD), etc. Gastric diseases including reflux, endocrinological diseases Recent use of psychoactive medication, including alcohol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>